Novel Orthopox Small Molecule Anti-Virals

Information

  • Research Project
  • 6789761
  • ApplicationId
    6789761
  • Core Project Number
    R43AI060151
  • Full Project Number
    1R43AI060151-01
  • Serial Number
    60151
  • FOA Number
    PAS-02-149
  • Sub Project Id
  • Project Start Date
    4/15/2004 - 20 years ago
  • Project End Date
    3/31/2006 - 18 years ago
  • Program Officer Name
    GREENSTONE, HEATHER LEA
  • Budget Start Date
    4/15/2004 - 20 years ago
  • Budget End Date
    3/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/15/2004 - 20 years ago
Organizations

Novel Orthopox Small Molecule Anti-Virals

DESCRIPTION (provided by applicant): The identification of agents that can either treat or halt the spread of smallpox or other diseases caused by orthopox viruses would have great benefit in mitigating the risk of the orthopox virus being used as a biological weapon. Furthermore such agents would be useful as a therapeutic for accidental exposure to other orthopox viruses such as the recently publicized cases of monkey pox caused by human exposure to exotic imported animals. The ideal therapeutic would be an effective and safe orally available small molecule that could be taken by individuals who were exposed to an orthopox virus or had active disease. Recent evidence suggests that the proteolytic activity of a novel protease encoded by the orthopox virus genome is an obligatory event for viral proliferation. Using a proprietary process of drug discovery called TTP Translational Technology TM that combines novel medicinal chemistry with computer modeling and a series of in vitro biological screening assays, TransTech Pharma proposes to discover small molecule inhibitors of the orthopox protease that have drug like characteristics in terms of potency, safety and pharmacokinetic characteristics as a first step in developing a therapeutic anti-viral for the treatment of infections caused by the orthopox virus.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    352188
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:352188\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    TRANSTECH PHARMA, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HIGH POINT
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    27265
  • Organization District
    UNITED STATES